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Introduction. Patients with high-grade sarcoma (HGS) frequently develop metastatic disease thus limiting their long-term survival.
Lungmetastases (LM)have historically been treatedwith surgical resection (metastasectomy).Apotential alternative for controlling
LM could be stereotactic body radiation therapy (SBRT). We evaluated the outcomes from our institutional experience utilizing
SBRT. Methods. Sixteen consecutive patients with LM from HGS were treated with SBRT between 2009 and 2011. Routine
radiographic and clinical follow-up was performed. Local failure was defined as CT progression on 2 consecutive scans or growth
after initial shrinkage. Radiation pneumonitis and radiation esophagitiswere scored usingCommonToxicityCriteria (CTC) version
3.0. Results. All 16 patients received chemotherapy, and a subset (38%) also underwent prior pulmonary metastasectomy. Median
patient age was 56 (12–85), andmedian follow-up time was 20months (range 3–43). A total of 25 lesions were treated and evaluable
for this analysis. Most common histologies were leiomyosarcoma (28%), synovial sarcoma (20%), and osteosarcoma (16%). Median
SBRT prescription dose was 54Gy (36–54) in 3-4 fractions. At 43 months, local control was 94%. No patient experienced G2-4
radiation pneumonitis, and no patient experienced radiation esophagitis. Conclusions. Our retrospective experience suggests that
SBRT for LM from HGS provides excellent local control and minimal toxicity.
1. Introduction
Although sarcomas are rare, accounting for less than 1% of
cancers in adults, 20–40% of all sarcoma patients ultimately
develop metastatic disease in the lungs [1–4]. Of the high-
grade sarcomas (HGS), 40–60% of patients will develop lung
metastases (LM), of which 70–80% will have disease limited
to the lungs, likely through hematogenous spread.The devel-
opment of lung metastatic disease is associated with poor
outcomes as few patients achieve durable disease control [5].
Many sarcomas have a unique biological predilection for the
lung, often the only signs ofmetastatic disease, and, therefore,
controlling these specific sites of progression can increase
survival.
Due to this predilection of HGS for the lungs, surgical
resection has been a vital part of managing these patients.
Reported 5-year overall survival rates following metasta-
sectomy vary from 20 to 40% depending upon the patient
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selection [5–10]. Over the past two decades, many groups
have published results demonstrating successful palliation
and even prolongation of survival after resection of LM from
HGS [11]. Nearly 80%of the patients, however, will experience
recurrent pulmonary disease even after a complete oncologic
resection [8, 12–16].
Radiation therapy is another local modality that has been
used for treatingmetastatic disease in the chest. Traditionally,
radiation has had a limited, typically palliative role in the
management of LM due to limited radiation tolerance of
the lung. Achievements in radiation technique, dose delivery,
image guidance, and precision have expanded indications for
RT in the management of pulmonary disease.
With the development of stereotactic body radiation
therapy (SBRT), high biologic doses of radiation using a
precise arrangement of beams to target the tumor plus a small
margin can be delivered,minimizing dose to the surrounding
normal tissue. In primary nonsmall cell lung cancer, SBRT is
becoming a standard therapeutic option for medically inop-
erable patients. The Radiation Therapy Oncology Group
(RTOG) phase II trial reported a 3-year local control 97.6%
with 54Gy in 3 fractions [17]. Retrospective data have demon-
strated equivalently high and durable local control using
SBRT, approaching that of lobar resection [18]. Several insti-
tutions have utilized SBRT for the treatment of pulmonary
oligometastatic disease [19, 20]. Investigators at theUniversity
of Colorado recently reported a 96% local control rate in 38
patients with 63 lung lesions in phase II trial [20].
At our institution,we also have treated a cohort of patients
with metastatic HGS in the lungs with SBRT after a consen-
susv recommendation by our multidisciplinary tumor board.
Based on our results with treating early-stage NSCLC, we
hypothesized that SBRT would be an efficacious approach for
patients with LM from HGS.
2. Materials and Methods
From March 2009 to October 2011 we treated a cohort of 16
consecutive patients with LM from HGS with linear accel-
erator-based SBRT at the University of California, Los Ange-
les, Department of Radiation Oncology. The institutional
review board approved this study. Cases suitable for SBRT
were selected after multidisciplinary evaluation at thoracic
tumor board based upon high operative risk, refusal of
surgery, documented metastatic disease outside of the lung,
prior thoracotomy, and/or inability to tolerate lobectomy.
Upon the first diagnosis of LM fromHGS, patient and tumor
characteristicswere gathered, and then evaluation for surgical
resection, chemotherapy, or potentially SBRTwas completed.
All patients did not receive surgical therapy but did receive
some sort of systemic chemotherapy depending on the diag-
nosis. The lung had not received any sort of conventional
radiation prior to the delivery of SBRT.
2.1. Simulation/Contours/Treatment. During simulation, all
patients were immobilized with a vacuum bag in the supine
arms-up position and underwent four-dimensional CT sim-
ulation (4DCT), obtaining 2.5mm slices with free-breathing
approach. The 4DCT generated an actual volumetric spa-
tiotemporal anatomical data set by binning corresponding
images from all couch positions into different volumes. Ulti-
mately, 4 separate CT data sets were generated: original con-
trast CT simulation scan, end-expiratory, 50% expiration, and
end-inspiratory for target volume definition.
To account for tumor motion, an internal target volume
(ITV) was generated by contouring the gross tumor volume
(GTV) on each of the four volume sets defined as tumor seen
on lung windows. To create the final planning target volume
(PTV), 0.3 cmmarginswere added in the lateral, anterior, and
posterior dimensions, while 0.6 cm margins were added in
the superior-inferior margins, making adjustments for other
critical structures of avoidance such as the rib cage.The heart,
lungs, esophagus,proximal tracheobronchial tree, spinal cord,
and brachial plexus were contoured according to the guide-
lines detailed in RTOG 0236.
Treatment planning was performed using the iPLAN sys-
tem (BrainLAB, AG, Heimstetten, Germany), prescribing to
cover 95% of the PTVwith the prescription dose delivered by
multiple coplanar and noncoplanar conformal arcs or inten-
sity modulated fields. Total dose and dose per fraction deliv-
ered were primarily 54Gy in 3 fractions (18Gy per fraction)
or 50Gy in 4 fractions (12.5 Gy per fraction) for more central
lesions. A central lesionwas defined as a tumorwithin 2 cmof
the proximal bronchial tree (RTOG definition) [21]. Two
patients received 36Gy in 3 fractions and one patient received
42Gy in 3 fractions, as they were part of an institutional com-
bined SBRT and radiofrequency ablation (RFA) protocol. We
adhered to the organ tolerance dose limits as specified by
RTOG 0236 for peripheral tumors and with modified dose
limits for a 4-fraction regimen.
Stereoscopic and volumetric-based image-guidance were
employed prior to each fraction. Respiratory gating was not
employed.All patientswere treated on theNovalis TX system,
using Novalis ExacTrac patient positioning platform (Brain-
LAB, AG, Heimstetten, Germany). Patients received a cone
beam CT scan prior to each fraction to ensure that the plan
corresponded correctly to the patient’s anatomy during treat-
ment, and adjustments were made accordingly.
2.2. Chart Review. Routine follow-up included history and
physical examination and a contrast-enhanced chest CT scan
every 3–6 months after treatment. FDG-PET scans were only
acquired if there was a concern for gross tumor recurrence
in the background of an inflammatory lung reaction. All
other inpatient/outpatient hospital notes, follow-up notes,
and imaging were reviewed. In particular, we asked patients
if they were experiencing fatigue, dyspnea, chest-wall pain,
hemoptysis, or cough at their first follow-up visit at 3months.
The specific toxicities of radiation pneumonitis (RP) and
radiation esophagitis (RE) were tracked longitudinally and
scored on basis of Grade 0-1 (asymptomatic or no treatment)
versus Grades 2–5 using the National Cancer Institute com-
mon toxicity criteria (CTC) version 3.0.
2.3. Statistical Analysis. The primary endpoint for this study
was local control and the secondary endpoint was actuarial
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overall survival, estimated usingKaplan-Meiermethod.Gross
tumor volume and the biologic equivalent dose (BED) were
calculated for each individual lesion.The BEDwas calculated
using the linear quadratic (LQ) formula:
BED = 𝑑 [1 + 𝑑/𝑛
𝛼/𝛽
] , (1)
assuming an𝛼/𝛽 ratio of 10 for the tumor (𝑛=number of frac-
tions, 𝑑 = total dose) [22]. Local failure was scored as an even
if a treated lesion grew at any point on axial slices on 2 consec-
utive CT scans based on a radiographic evaluation or growth
after initial shrinkage.
Local control was defined as not having local failure at the
time of the analysis (CTprogression on two consecutive scans
or tumor growth after initial shrinkage). Progression-free
survival was defined as the time between the first day of SBRT
to local failure, or last follow-up. Overall survival was defined
as the time between the first day of SBRT to death, or last
follow-up.
3. Results
Patient demographics and tumor characteristics are pre-
sented in Table 1. All patients received chemotherapy and
a subset also underwent prior pulmonary metastasectomies
(38%). The mean and median durations from the develop-
ment of metastatic disease to lung SBRT were 19.6 and 13.7
months, respectively. One patient had RFA to a separate
lesion prior to SBRT, while 2 patients had RFA to the radiated
lesionwithin 7 days after SBRTon an institutional prospective
protocol. Fifteen of 16 patients had chemotherapy prior to
SBRT, and twelve of 16 patients had chemotherapy after SBRT.
Five of 16 (31.3%) patients developed subsequent pulmonary
recurrences after SBRT.
A total of 25 (76% soft tissue sarcoma, 24% bone sarcoma)
lesionswere treated and evaluable for this analysis (1–3 lesions
treated at any given radiation session), of which 76% were
noncentral lesions. Most common histologies were leiomyo-
sarcoma (28%), synovial sarcoma (20%), and osteosarcoma
(16%). Median patient age was 56 years (range: 12–85) and
median follow-up time was 20 months (range: 3–43 months)
for local control, and 25 months (range: 19–48 months) for
overall survival. Median SBRT prescription dose was 54Gy
(range: 36–54Gy) in 3-4 fractions (majority receiving 54Gy
in 3 fractions). Median PTV volume was 9.2 cm3 (range: 1.8–
84.9 cm3).
At 43 months, there was one local failure (LC = 94%) in
this cohort (Figure 1).The single failure occurred in a 72-year-
old male, diagnosed with prostate leiomyosarcoma in 2008
and subsequent lung metastasis in the right upper lobe in
2010. The patient underwent 54Gy in 3 fractions for an 11 by
10mm lesion. SBRT was given with sequential gemcitabine
chemotherapy. After 6 months, the lesion measured 6 by
3mm. After 10 months from treatment, CT showed increase
in the size of the lesion to 13 by 11mm. But, because the lesion
initially decreased in size and then demonstrated subsequent
growth, we categorized this as a local failure. That lesion has
since then remained unchanged.The patient has been treated
Table 1: Patient and tumor characteristics.
Age at time of treatment (years)
Median 56
Range 12–85
Patients (𝑛 = 16)
Male 7 (44%)
Female 9 (56%)
Lesions (𝑛 = 25)
Peripheral 19 (76%)
Central 6 (24%)
Histology
Leiomyosarcoma 7
Synovial cell 5
Osteosarcoma 4
Liposarcoma 2
NOS 2
Spindle cell 1
Chondrosarcoma 1
Liposarcoma 1
Hemangiopericytoma 1
Embryonal 1
Dose fractionation and BED∗
54Gy, 3 fractions (BED = 151.2 Gy) 13 (52%)
50Gy, 4 fractions (BED = 112.5 Gy) 9 (36%)
36Gy, 3 fractions (BED = 79.2Gy) 2 (8%)
42Gy, 3 fractions (BED = 100.8Gy) 1 (4%)
∗Biological equivalent dose is calculated per (1), assuming 𝛼/𝛽 ratio of 10 for
tumor (𝑛 = number of fractions, 𝑑 = total dose).
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Figure 1: Local control. Actuarial local control estimated for the
entire cohort using the Kaplan-Meier method.
with taxotere and doxorubicin and is currently on a clinical
trial with pazopanib. He has since then developed multiple
subcentimeter nodules in the lung that have been stable on
the trial drug.
Overall survival at 4 years was 72% (Figure 2). No patient
experienced Grades 2–4RP (Table 2), which are symptoms
of shortness of breath requiring steroids and/or diuretics or
4 Sarcoma
1.0
0.8
0.6
0.4
0.2
0.0
0 10 20 30 40 50
Months
16 16 14 5 3 0
Censored
Cu
m
ul
at
iv
e o
ve
ra
ll 
su
rv
iv
al
Patient at risk
Figure 2: Overall survival. Actuarial overall survival estimated for
the entire cohort using the Kaplan-Meier method.
Table 2: Adverse events (CTC, version 3.0): pneumonitis.
Grade 0 1 (4%)
Grade 1 24 (96%)
Grades 2–4 0
worse. All but one patient had radiographic changes on the
posttreatment CT, classified as Grade I RP. No patients expe-
riencedRE.No untoward late complications of the treatments
were seen in these patients, although the follow-up time is
limited.
4. Discussion
Metastatic disease historically portends a poor prognosis in
cancer regardless of the histology of the primary. In partic-
ular, in HGS, patients with lung metastases unaddressed by
surgical management have a median overall survival of 8–14
months [6, 8, 23]. Although there are no prospective random-
ized trials comparing pulmonary metastasectomy to obser-
vation, it is generally accepted that in patients with limited
extrapulmonary metastatic disease, surgical resection of LM
improves overall survival. Five-year survival rates in patients
with LM from STS after surgical management range from 21
to 43% [1, 23]. Therefore, given the unique biology of many
sarcomas, controlling sites of metastatic disease in the lung
assuming the primary tumor site is managed appropriately
can potentially increase long-term survival [6, 11].
Although primary surgical management remains the
primarymodality of treatment, our series supports the ability
of SBRT to successfully control focal metastatic disease and
extend survival in properly selected patients. Out of 25
lesions, there was 1 local progression and 78% survival at 4
years. In comparison, another recent dual-institution analysis
treated 74 pulmonary lesions secondary to soft tissue sarcoma
with SBRT using 50Gy in 5 fractions, reporting a Kaplan-
Meier estimate of 88% LC at 2 years and 82% at 3 years [24].
Taken together, SBRT is an attractive and promising alter-
native to surgery for oligometastatic disease to the lung from
HGS. Given the excellent local control, andmore importantly
the overall survival in this series, SBRT may confer similar
disease-specific and overall survival benefits to surgery. How-
ever, a prospective study is needed to validate these findings.
Most importantly, in our cohort, the management of LM
with SBRT is associated with a favorable toxicity profile with
the absence of symptomatic RP and RE. In one study, symp-
tomatic grade 2–4RP has been shown to be correlated with
themean lung dose and theV20 (volume of the lung receiving
more than 20Gy) [25], which can help to plan the radiation
accordingly to minimize the chances of such subacute effects
in the lung. Guckenberger et al. demonstrated that the onset
of symptomatic pneumonitis is generally later than conven-
tionally fractionated therapy, occurring in 10% of patients at a
median interval of 5months [26]. RTOG0236 reported 12.7%
Grade 3 and 3.6% Grade 4 protocol specified treatment-
related adverse events. Since then, more attention has been
paid to tailoring a dose according to the tumor volume, loca-
tion, and proximity to central critical structures as well as
skin, chest wall, and brachia plexus. Therefore, we can use
prior studies of SBRT to determine therapeutic doses and
potentially even use a BED calculation to come up with an
effective yet safe dose tominimize the chance of pneumonitis,
bronchial stenosis, and fistula [27, 28].
Furthermore, in selecting patients appropriate for SBRT,
we can start with the vast literature providing prognostic
variables that affect survival after surgery [1, 11, 14, 29]. Poten-
tial considerations include control of primary site of disease,
other distant sites of metastases, disease-free interval prior
to LM, probability of complete resection of all pulmonary
lesions, location of lesions (laterality), histologic grade,
amount of parenchyma needed to be removed, adequate
cardiopulmonary reserve, and responsiveness to systemic
chemotherapy and/or biologic agents. In addition, the deci-
sion to treat such a unique and variable demographic range of
patients will likely depend on age, predicted survival, rapidity
of disease progression, morbidity of procedure, capacity to
recover, and patient preference. It is in this arena that SBRT
can provide support to the surgical management of these
patients due to its efficacy and lack of serious side effects.
Nevertheless, there are several limitations to our single
institutional study, including the small sample size, tumor
and biologic heterogeneity, dose variation, and selection of
patients, all of which were unavoidable when evaluating such
a subset of a given population. Although we report an excel-
lent overall survival, this is more likely secondary to the spe-
cific biology of the disease and appropriate patient selection.
In our population, selection biasmay have occurred in oppos-
ing directions where SBRT was indicated due to their favor-
able small size and/or multiple locations, and in other times
where surgery is unlikely due to the larger size of a lesion that
may have been too central, requiring a pneumonectomy.
The reported safety and efficacy of treating LM are con-
sistent in the literature, extrapolated from the much more
extensive experience of treatingmetastatic disease in the lung
from other primaries. Dating back to 2006, the University of
Chicago group had reported a 3-year actuarial control rate of
82.5% out of 125 lung lesions treated from various primary
malignancies [30]. SBRT may also be especially suitable for
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managing lung metastases because of the lack of concern
for lymph node metastases and the fact that many sarcoma
patients may have preserved lung function as opposed to pri-
mary lung cancer patients typically complicated by smoking
and chronic obstructive pulmonary disease.
5. Conclusions
Our single-institutional experience suggests that SBRT for
pulmonary metastases from HGS provides excellent local
control with minimal toxicity. As our ability to radiographi-
cally detect small areas of disease increases, the practical effi-
cacy of high-dose SBRT can be advantageous as it is an attrac-
tive less-invasive alternative for patients with high operative
risk. Durable local control of pulmonary metastases can pre-
serve the quality of life and likely also translate into an overall
survival advantage in the same way the standard of care,
metastasectomy, has demonstrated. The lack of hospitaliza-
tion, efficiency, and safety of SBRTmakes it an especially suit-
able back-up to surgery especially as the probability of a com-
plication outweighs the potential benefit in high-risk or previ-
ously operated patients.
In the context of adjuvant chemotherapy andmolecularly
targeted agents, SBRT canwork alongwithmetastasectomy to
provide long-term survival and prevent/alleviate symptoms
in patients with metastatic HGS to the lungs. Furthermore,
larger prospective studies need to be completed to determine
specific selection criteria for the utilization of SBRT for HGS
patientswith LM.Also,modern techniques such asmolecular
profiling may provide insight as which patients are likely
to have lung only metastatic disease, and thus benefit from
local therapy. At our institution, a phase II feasibility study is
planned to prospectively validate our findings.
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